An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

NCT07226934 | Recruiting

• 1 other identifier: 202509134
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore patterns in questions generated by WashU ChatGPT. Patients will also provide feedback pertaining to the perceived helpfulness and ease-of-use of WashU-ChatGPT-generated question lists, as well as their attitudes and intentions regarding use of AI chatbots and whether they would engage in pre-appointment AI-assisted question brainstorming independently in the future.

Conditions

Lymphoma; Multiple Myeloma

Keywords

Generative Artificial Intelligence; Healthcare; Cancer; Communication

Outcome Measures

Primary Outcomes (1)

• Changes in communicative self-efficacy

  * Communicative self-efficacy is measured by Self-efficacy survey . * Dependent samples t-tests will be used to assess within-subject changes. * The Self-Efficacy survey consists of two scales containing 10 questions each, with answers ranging from 1=not successful to 5=very successful or 1=not confident to 5=very confident. The total score on each scale ranges from 10-50 with a higher score on Scale 1 (the PEPPI-5) representing higher self-efficacy related to communicating with physicians in general and a higher score on Scale 2 (researcher-designed questions based on Social Cognitive Theory) representing higher self-perceived success at communication with the physician during the immediately preceding appointment.

  Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

Secondary Outcomes (4)

• Changes in perceived amount of cancer information received as measured by an abbreviated version the EORTC QLQ - INFO25

  Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

• Changes in satisfaction with cancer information received as measured by the EORTC QLQ - INFO25

  Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

• Changes in the number of questions asked during appointments

  Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

• Changes in self-reported degree of intention to use AI chatbots for healthcare tasks

  Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

Study Arms (1)

GPT-QPL: An AI-Generated, Personalized Question Prompt List

EXPERIMENTAL

Participants will complete surveys at appointment 1 (pre-intervention) and after being provided the AI-Generated, Personalized Question Prompt List at appointment 2 (post-intervention).

Other: GPT-QPL

Interventions

GPT-QPL OTHER

A research team member will generate a QPL that is personalized to the patient's demographics (from EHR screening and Baseline Demographic Survey) and concerns (from Distress Thermometer Problem Checklist and Interview).

Also known as: AI-Generated, Personalized Question Prompt List

GPT-QPL: An AI-Generated, Personalized Question Prompt List

Eligibility Criteria

• Age: 20 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

Eligibility Criteria as determined by Electronic Health Record (EHR) Screening: * Documented diagnosis of lymphoma, as defined by ICD-10 codes C81-C88 or multiple myeloma, as defined by ICD codes C90.0-C90.02 * Has a scheduled follow-up appointment at a participating outpatient oncology clinic within the next month. Participating clinics include: * Dr. David Russler-Germain: Outpatient Lymphoma Clinic * Dr. Michael Slade: Outpatient Multiple Myeloma Clinic * Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks. * For eligible patients with lymphoma, this includes, but is not limited to, commonly prescribed treatment combinations such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin/Hydroxydaunorubicin, Vincristine, and Prednisone) for Non-Hodgkin Lymphoma, or ABVD (Adriamycin/Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) for Hodgkin Lymphoma-both regimens that are frequently administered every three weeks * For patients with multiple myeloma, eligibility will include patients in the "induction" phase of chemotherapy treatment, which frequently requires patients to come in for outpatient appointments once every four weeks as well as patients in a maintenance phase of treatment that otherwise requires them to attend outpatient appointments at a frequency of every one to four weeks * Between age 20-99 at enrollment (Patients aged 18-19 and older than 99 will be excluded so that the study team is able to elicit questions from WashU ChatGPT using a standardized prompt that describes the patient's age only as specifically as a 10-year decade range (i.e., "I am a patient in my 20's, 30's, 40's, etc.). * Able to consent to medical care independently (does not have a legally authorized representative or documented diagnosis of cognitive impairment) Eligibility Criteria as determined by subsequent recruitment phone call or In-person approach after a clinic appointment: * Does not have visual impairments or English literacy limitations that would interfere with ability to engage in an intervention that requires being able to read material on an electronic device and on paper and communicate aloud during appointments with health care providers, based on patient self-report * Able to use email (consent form will be distributed electronically through DocuSign and associated emails), based on successful completion of electronic informed consent

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Washington University School of Medicine: lead

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

RECRUITING

Related Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

MeSH Terms

Conditions

Lymphoma; Multiple Myeloma; Neoplasms; Communication

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Behavior

Study Officials

• Jessica Hahne, MA, MPH

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jessica Hahne, MA, MPH

CONTACT

314-935-6173; hahne.j@wustl.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 7, 2025
• First Posted: November 12, 2025
• Study Start: December 26, 2025
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: March 25, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)